Epinastine (BioDeep_00000033260)

   

human metabolite blood metabolite


代谢物信息卡片


2,4-diazatetracyclo[12.4.0.0²,⁶.0⁷,¹²]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine

化学式: C16H15N3 (249.126591)
中文名称: 依匹斯汀
谱图信息: 最多检出来源 Homo sapiens(blood) 12.5%

分子结构信息

SMILES: C1C2C3=CC=CC=C3CC4=CC=CC=C4N2C(=N1)N
InChI: InChI=1S/C16H15N3/c17-16-18-10-15-13-7-3-1-5-11(13)9-12-6-2-4-8-14(12)19(15)16/h1-8,15H,9-10H2,(H2,17,18)

描述信息

Epinastine is used for the prevention of itching associated with allergic conjunctivitis. It has a multi-action effect that inhibits the allergic response in 3 ways: 1. stabilizes mast cells by preventing mast cell degranulation to control the allergic response, 2. prevents histamine binding to both the H1- and H2-receptors to stop itching and provide lasting protection, and 3. prevents the release of proinflammatory chemical mediators from the blood vessel to halt progression of the allergic response.
R - Respiratory system > R06 - Antihistamines for systemic use > R06A - Antihistamines for systemic use
D018377 - Neurotransmitter Agents > D018494 - Histamine Agents > D006633 - Histamine Antagonists
S - Sensory organs > S01 - Ophthalmologicals > S01G - Decongestants and antiallergics
C308 - Immunotherapeutic Agent > C29578 - Histamine-1 Receptor Antagonist
Epinastine (WAL801) is an antihistamine and mast cell stabilizer. Epinastine is a potent, selective and orally-active histamine H1 receptor antagonist. Epinastine also inhibits IL-8 release and has an antiallergic action[1][2][3][4].

同义名列表

16 个代谢物同义名

2,4-diazatetracyclo[12.4.0.0²,⁶.0⁷,¹²]octadeca-1(18),3,7,9,11,14,16-heptaen-3-amine; 3-Amino-9,13b-dihydro-1H-dibenz(c,F)imidazo(1,5-a)azepine; 3-Amino-9,13b-dihydro-1H-benz(c,F)imidazo(1,5a)azepine; Epinastine hydrochloride; (+-)-Epinastine; Epinastinum; Epinastina; WAL 801 CL; Epinastine; WAL 801CL; WAL-80 CL; Flurinol; Purivist; WAL 801; WAL 80; WAL801



数据库引用编号

10 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。



文献列表

  • Mark J Henderson, Kathleen A Trychta, Shyh-Ming Yang, Susanne Bäck, Adam Yasgar, Emily S Wires, Carina Danchik, Xiaokang Yan, Hideaki Yano, Lei Shi, Kuo-Jen Wu, Amy Q Wang, Dingyin Tao, Gergely Zahoránszky-Kőhalmi, Xin Hu, Xin Xu, David Maloney, Alexey V Zakharov, Ganesha Rai, Fumihiko Urano, Mikko Airavaara, Oksana Gavrilova, Ajit Jadhav, Yun Wang, Anton Simeonov, Brandon K Harvey. A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. Cell reports. 2021 04; 35(4):109040. doi: 10.1016/j.celrep.2021.109040. [PMID: 33910017]
  • Shouma Ishikawa, Atsushi Sawamoto, Satoshi Okuyama, Mitsunari Nakajima. T-Cell Activation-Inhibitory Assay to Screen Caloric Restriction Mimetics Drugs for Drug Repositioning. Biological & pharmaceutical bulletin. 2021; 44(4):550-556. doi: 10.1248/bpb.b20-00889. [PMID: 33790105]
  • Seung-Hyun Jeong, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee. Simultaneous measurement of epinastine and its metabolite, 9,13b-dehydroepinastine, in human plasma by a newly developed ultra-performance liquid chromatography-tandem mass spectrometry and its application to pharmacokinetic studies. Biomedical chromatography : BMC. 2020 Sep; 34(9):e4848. doi: 10.1002/bmc.4848. [PMID: 32302007]
  • Seung-Hyun Jeong, Ji-Hun Jang, Hea-Young Cho, Yong-Bok Lee. Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays. Molecules (Basel, Switzerland). 2020 Jan; 25(1):. doi: 10.3390/molecules25010209. [PMID: 31947890]
  • C Iwasa, K Zaima, K Metori, N Harikai, Y Tanaka, J Hamada, K Shinomiya, H Hayashi. Transfer of epinastine to infants through human breast milk. Die Pharmazie. 2019 12; 74(12):732-736. doi: 10.1691/ph.2019.9105. [PMID: 31907112]
  • Girish G Ariga, Praveen N Naik, Sharanappa T Nandibewoor, Shivamurti A Chimatadar. Study of fluorescence interaction and conformational changes of bovine serum albumin with histamine H₁ -receptor--drug epinastine hydrochloride by spectroscopic and time-resolved fluorescence methods. Biopolymers. 2015 Nov; 103(11):646-57. doi: 10.1002/bip.22707. [PMID: 26215421]
  • Yasuto Kido, Pär Matsson, Kathleen M Giacomini. Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. Journal of medicinal chemistry. 2011 Jul; 54(13):4548-58. doi: 10.1021/jm2001629. [PMID: 21599003]
  • Nao Ono, Yuji Miyamoto, Takako Ishiguro, Keiichi Motoyama, Fumitoshi Hirayama, Daisuke Iohara, Hakaru Seo, Satoshi Tsuruta, Hidetoshi Arima, Kaneto Uekama. Reduction of bitterness of antihistaminic drugs by complexation with β-cyclodextrins. Journal of pharmaceutical sciences. 2011 May; 100(5):1935-43. doi: 10.1002/jps.22417. [PMID: 21374625]
  • Yu-ichiro Mochizuki, Atsuko Furuta, Ayako Furuya, Ken-ichi Kanai, Kazuhito Asano, Harumi Suzaki. Suppressive activity of epinastine hydrochloride on eosinophil activation in vitro. In vivo (Athens, Greece). 2008 Jan; 22(1):13-20. doi: NULL. [PMID: 18396776]
  • Luciana Vera-Candioti, Alejandro C Olivieri, Héctor C Goicoechea. Simultaneous multiresponse optimization applied to epinastine determination in human serum by using capillary electrophoresis. Analytica chimica acta. 2007 Jul; 595(1-2):310-8. doi: 10.1016/j.aca.2007.04.032. [PMID: 17606014]
  • Kazuhiko Hanashiro, Masanori Sunagawa, Toshiyuki Nakasone, Mariko Nakamura, Tadayoshi Kosugi. Inhibition of IgE-mediated phosphorylation of FcepsilonRIgamma protein by antiallergic drugs in rat basophilic leukemia (RBL-2H3) cells: a novel action of antiallergic drugs. International immunopharmacology. 2007 Jul; 7(7):994-1002. doi: 10.1016/j.intimp.2007.02.017. [PMID: 17499203]
  • Masahiko Toyoda, Motokazu Nakamura, Hidemi Nakagawa. Distribution to the skin of epinastine hydrochloride in atopic dermatitis patients. European journal of dermatology : EJD. 2007 Jan; 17(1):33-6. doi: 10.1684/ejd.2007.0098. [PMID: 17324825]
  • Kimihiro Okubo, Minoru Gotoh. Inhibition of the antigen provoked nasal reaction by second-generation antihistamines in patients with Japanese cedar pollinosis. Allergology international : official journal of the Japanese Society of Allergology. 2006 Sep; 55(3):261-9. doi: 10.2332/allergolint.55.261. [PMID: 17075266]
  • Kunio Izu, Yoshiki Tokura. The various effects of four H1-antagonists on serum substance P levels in patients with atopic dermatitis. The Journal of dermatology. 2005 Oct; 32(10):776-81. doi: 10.1111/j.1346-8138.2005.tb00844.x. [PMID: 16361727]
  • A Sarashina, S Tatami, N Yamamura, Y Tsuda, T Igarashi. Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children. British journal of clinical pharmacology. 2005 Jan; 59(1):43-53. doi: 10.1111/j.1365-2125.2005.2250. [PMID: 15606439]
  • Naoki Ishiguro, Takashi Nozawa, Akiko Tsujihata, Asami Saito, Wataru Kishimoto, Kazutoshi Yokoyama, Takafumi Yotsumoto, Kenji Sakai, Takashi Igarashi, Ikumi Tamai. Influx and efflux transport of H1-antagonist epinastine across the blood-brain barrier. Drug metabolism and disposition: the biological fate of chemicals. 2004 May; 32(5):519-24. doi: 10.1124/dmd.32.5.519. [PMID: 15100174]
  • Naro Ohashi, Takeshi Sugiura, Taisuke Isozaki, Tatsuo Yamamoto, Akira Hishida. Anti-glomerular basement membrane antibody-induced glomerulonephritis with periglomerular granulomatous reaction and massive renal eosinophilic infiltration. American journal of kidney diseases : the official journal of the National Kidney Foundation. 2003 Sep; 42(3):E28-35. doi: 10.1016/s0272-6386(03)00802-3. [PMID: 12955709]
  • Hirotake Ozaki, Takashi Matsuyama, Yo Kawakubo, Motomi Miyahara, Akira Ozawa. A case of type IV solar urticaria identified by reverse in vitro serum test. The Tokai journal of experimental and clinical medicine. 2003 Jul; 28(2):51-5. doi: NULL. [PMID: 14714829]
  • T Ogiso, M Kasutani, H Tanaka, M Iwaki, T Tanino. Pharmacokinetics of epinastine and a possible mechanism for double peaks in oral plasma concentration profiles. Biological & pharmaceutical bulletin. 2001 Jul; 24(7):790-4. doi: 10.1248/bpb.24.790. [PMID: 11456119]
  • T Ohmura, M Chachin, S Tarui, A Nagakura, T Igarashi, H Ikeda, K Ikegami, H Kitagawa, S Uchida. Effects of terfenadine, astemizole and epinastine on electrocardiogram in conscious cynomolgus monkeys. European journal of pharmacology. 1999 Aug; 378(2):169-75. doi: 10.1016/s0014-2999(99)00457-4. [PMID: 10478629]
  • K Ohmori, H Manabe, K Akuta-Ohnuma. Inhibitory effect of oxatomide on oxygen-radical generation and peptide-leukotriene release from guinea pig eosinophils. Arzneimittel-Forschung. 1998 Jan; 48(1):43-6. doi: NULL. [PMID: 9522030]
  • H Ohtani, H Kotaki, Y Sawada, T Iga. A comparative pharmacokinetic-pharmacodynamic study of the electrocardiographic effects of epinastine and terfenadine in rats. The Journal of pharmacy and pharmacology. 1997 Apr; 49(4):458-62. doi: 10.1111/j.2042-7158.1997.tb06824.x. [PMID: 9232548]
  • H Ohtani, H Kotaki, Y Sawada, T Iga. Quantitative determination of epinastine in plasma by high-performance liquid chromatography. Journal of chromatography. B, Biomedical applications. 1996 Aug; 683(2):281-4. doi: 10.1016/0378-4347(96)00094-1. [PMID: 8891928]
  • K Yanai, J H Ryu, T Watanabe, R Iwata, T Ido, M Asakura, R Matsumura, M Itoh. Positron emission tomographic study of central histamine H1-receptor occupancy in human subjects treated with epinastine, a second-generation antihistamine. Methods and findings in experimental and clinical pharmacology. 1995 Nov; 17 Suppl C(?):64-9. doi: NULL. [PMID: 8750798]
  • C Kamei, M Akagi, M Mio, K Kitazumi, K Izushi, S Masaki, K Tasaka. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (I). Elucidation of the mechanism for histamine release inhibition. Immunopharmacology and immunotoxicology. 1992; 14(1-2):191-205. doi: 10.3109/08923979209009219. [PMID: 1375955]
  • C Kamei, K Izushi, Y Adachi, M Shimazawa, K Tasaka. Inhibitory effect of epinastine on the type II-IV allergic reactions in mice, rats and guinea pigs. Arzneimittel-Forschung. 1991 Nov; 41(11):1150-3. doi: NULL. [PMID: 1687348]